Patents by Inventor W. Mark Eickhoff

W. Mark Eickhoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF MIGRAINE
    Publication number: 20250064788
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: November 12, 2024
    Publication date: February 27, 2025
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Treatment of migraine
    Patent number: 12220408
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: July 18, 2024
    Date of Patent: February 11, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie J. Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TREATMENT OF MIGRAINE
    Publication number: 20250009722
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: September 19, 2024
    Publication date: January 9, 2025
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Treatment of migraine
    Patent number: 12168004
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: May 13, 2024
    Date of Patent: December 17, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie J. Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TREATMENT OF MIGRAINE
    Publication number: 20240366575
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TREATMENT OF MIGRAINE
    Publication number: 20240299369
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Tablet formulation for CGRP active compounds
    Patent number: 11925709
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 12, 2024
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
    Publication number: 20230248655
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
    Publication number: 20210085612
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 25, 2021
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
    Publication number: 20190209478
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Application
    Filed: November 2, 2018
    Publication date: July 11, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Tablet formulation for CGRP active compounds
    Patent number: 10117836
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 6, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
    Publication number: 20160346214
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Application
    Filed: January 30, 2015
    Publication date: December 1, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Formulations for therapeutic agents absorbed through mucous membranes
    Publication number: 20030054045
    Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
    Type: Application
    Filed: June 21, 2002
    Publication date: March 20, 2003
    Applicant: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
  • Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract
    Patent number: 6432381
    Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: August 13, 2002
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
  • FORMULATIONS FOR THERAPEUTIC AGENTS ABSORBED THROUGH MUCOUS MEMBRANES
    Publication number: 20010006617
    Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
    Type: Application
    Filed: March 11, 1997
    Publication date: July 5, 2001
    Inventors: GARY G. LIVERSIDGE, W. MARK EICKHOFF, KATHLEEN J. ILLIG, PRAMOD SARPOTDAR, STEPHEN B. RUDDY
  • Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
    Patent number: 5628981
    Abstract: Nanoparticulate crystalline x-ray contrast agents are formulated with stabilizers to enhance contact between the crystalline x-ray contrast agents and the gastrointestinal tract.Nanoparticulate crystalline therapeutic substances also formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: May 13, 1997
    Assignee: Nano Systems L.L.C.
    Inventors: Gary Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
  • Barium salt formulations stabilized by non-ionic and anionic stabilizers
    Patent number: 5593657
    Abstract: Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising nanoparticles of a barium salt having associated with its surface non-ionic and anionic stabilizers; and methods for their use in diagnostic radiology of the gastrointestinal tract.
    Type: Grant
    Filed: February 9, 1995
    Date of Patent: January 14, 1997
    Assignee: NanoSystems L.L.C.
    Inventors: Stephen B. Ruddy, W. Mark Eickhoff, Gary Liversidge, Mary E. Roberts
  • Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
    Patent number: 5585108
    Abstract: Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: December 17, 1996
    Assignee: Nanosystems L.L.C.
    Inventors: Stephen B. Ruddy, W. Mark Eickhoff, Gary Liversidge, Eugene R. Cooper
  • Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
    Patent number: 5580579
    Abstract: Nanoparticulate crystalline therapeutic or diagnostic substances formulated with stabilizers and high molecular weight, linear poly(ethylene oxide) polymers, enhance contact between the crystalline therapeutic or diagnostic substances and the gastrointestinal tract providing site-specific and extended therapeutic or diagnostic effect.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: December 3, 1996
    Assignee: Nano Systems L.L.C.
    Inventors: Stephen B. Ruddy, W. Mark Eickhoff, Gary Liversidge
  • Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
    Patent number: 5571536
    Abstract: Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 5, 1996
    Assignee: Nano Systems L.L.C.
    Inventors: W. Mark Eickhoff, Karl R. Mueller, David A. Engers